title: [Therapy of dyslipidemia in post-infarction: state of the art].
abstract: Between the risks factors involved in the atherogenesis LDL-cholesterol is determinant because highly associated to cardiovascular events. The primary target for the prevention of coronary diseases is a reduction of LDL-cholesterol because that reduces the cardiovascular mortality and the total mortality. The NCEP ATP III 2004 guide-lines propose as therapeutic target for the high-risk patients the reduction of plasma levels of LDL-cholesterol under 100 mg/dl and according to new trials under 70 mg/dl. The dyslipidaemia treatments are based on two approaches, i.e., the therapeutic lifestyle change and the pharmacological therapy. The available drugs are statins, fibrates, anion exchange resins, nicotinic acid. In the acute coronary syndrome patients is desirable to start immediately a therapy with statins since the hospital phase and direct the treatment to aggressive therapy. Unfortunately, the statin doses used in the most secondary prevention trials allow to get LDL-cholesterol under 100 mg/dl in the only half high-risk patients. The innovative therapeutic approach to hypercholesterolemia today is based on a double inhibition of cholesterol synthesis and absorption combining a statin with ezetimibe.
authors.affiliation: Dipartimento di Scienze Cliniche, Università Sapienza, Roma, Italia.
authors.forename: M C
authors.initials: MC
authors.lastname: Borgia
authors.forename: M
authors.initials: M
authors.lastname: Nardi
authors.forename: S
authors.initials: S
authors.lastname: Da Ros
authors.forename: V
authors.initials: V
authors.lastname: Castellano
mesh_terms: D000837:Anion Exchange Resins / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D002995:Clofibric Acid / Q000627:therapeutic use; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control* / Q000534:rehabilitation; D009525:Niacin / Q000627:therapeutic use; D040242:Risk Reduction Behavior
chemical_list: D000837:Anion Exchange Resins; D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D002995:Clofibric Acid; D000069438:Ezetimibe